Tavanta Therapeutics to Showcase Specialty Pipeline

Tavanta Therapeutics

KING OF PRUSSIA, PA — Tavanta Therapeutics, a clinical-stage specialty pharmaceutical company,  announced that it will present new data from its metastatic prostate cancer program during the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago, as well as from its anal fissure program during the upcoming American Society of Colon and Rectal Surgeons (ASCRS) Annual Meeting being held June 3-6 in Seattle.

“At ASCO, we will present detailed Phase 3 results for TAVT-45 that further demonstrate its potential to become the first FDA-approved oral suspension formulation of abiraterone acetate for patients with metastatic prostate cancer and provide a much-needed alternative for patients with dysphagia,” said Andreas Maetzel, M.D., Ph.D., Chief Medical Officer of  Tavanta Therapeutics.

“At ASCRS, we are excited to present the first data from our Phase 2 study of TAVT-119 in people with anal fissure. Currently, non-surgical options to treat anal fissures include topical nitrates (which are limited by headache/tolerability) and topical calcium channel blockers (which are only available via compounding pharmacies as none are FDA-approved for anal fissure). Based on the data that will be presented, we believe that TAVT-119 has the potential to offer patients a therapeutic option that is safe, efficacious and accessible.”

“We are pleased to highlight these promising new data, which reflect the significant progress of our clinical development programs,” said Lynne Powell, Chief Executive Officer of Tavanta Therapeutics.

Details of presentations are as follows:

ASCO Presentation

Poster: A Novel Abiraterone Acetate Oral Suspension for Patients with Metastatic Prostate Cancer: An Open-Label, Phase 3, Randomized Trial
Poster Number: 146
Date: Saturday, June 3, 2023
Poster Session Time:  The poster will be presented from 8:00 – 11:00 a.m. CDT, during the “Genitourinary Cancer—Prostate, Testicular, and Penile” poster session

READ:  MRO Named Top Healthcare Workplace USA

The Company’s abstract, which has been made available on the ASCO website can be viewed here. For more information about ASCO visit https://www.asco.org/.

ASCRS Presentation

Poster: Phase 2 Study of TAVT-119 (amlodipine besylate) Gel in Patients with Chronic Anal Fissure
Poster Number: eP600
Date: Monday, June 5, 2023
Poster Session Time:  An oral presentation of the ePoster will occur from 11:25 – 11:30 a.m. PDT, during the “ePoster Monitor 16 Benign Anorectal Disease” session

The Company’s abstract will be made available after the presentation on Tavanta’s website. For more information about ASCRS visit https://fascrs.org/.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.